Home Newsfeeds Ladenburg Thalmann Downgrades Allarity Therapeutics to Neutral

Ladenburg Thalmann Downgrades Allarity Therapeutics to Neutral

Ladenburg Thalmann analyst Aydin Huseynov downgrades Allarity Therapeutics (NASDAQ:ALLR) from Buy to Neutral.

byBenzinga Newsdesk

August 23, 2022

1 minute read

Ladenburg Thalmann analyst Aydin Huseynov downgrades Allarity Therapeutics (NASDAQ:ALLR) from Buy to Neutral.

Wells Fargo Maintains Equal-Weight on Guild Holdings, Lowers Price Target to $9

By Benzinga Newsdesk

November 4, 11:56 AM

Wells Fargo analyst Donald Fandetti maintains Guild Holdings (NYSE:GHLD) with a Equal-Weight and lowers the price target from $12 to $9.

GHLD

Broadway Financial Corporation Announces Terms Of 1-For-8 Reverse Stock Split

By Benzinga Newsdesk

October 31, 11:08 AM

Broadway Financial Corporation ("Broadway," "we," or the "Company") (Nasdaq Capital Market: BYFC), parent company of City First Bank, National Association, announced today the terms of the Company's previously disclosed

BYFC

‘Market’s Had A Very Solid Winning Streak Of Late’: Jim Cramer Eyes Key Retailers And CPI Data In Critical Earnings Week Ahead

By Nabaparna Bhattacharya

November 11, 3:18 PM

CNBC market analyst Jim Cramer emphasized the importance of the upcoming week for investors,

ACN

Novavax’s Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option

By Vandana Singh

February 2, 1:41 PM

Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024.

GSK

Ladenburg Thalmann Downgrades Allarity Therapeutics to Neutral

Related Posts

Wells Fargo Maintains Equal-Weight on Guild Holdings, Lowers Price Target to $9

Broadway Financial Corporation Announces Terms Of 1-For-8 Reverse Stock Split

‘Market’s Had A Very Solid Winning Streak Of Late’: Jim Cramer Eyes Key Retailers And CPI Data In Critical Earnings Week Ahead

Novavax’s Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option